Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02003612 · ClinicalTrials.gov registry record
Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia
A clinical trial, sponsored by Amgen.
- Completed
- Registry status
- 2,373
- Enrollment target
NCT02003612: Completed study, sponsored by Amgen.
NCT02003612 is a clinical trial that has completed, run by Amgen. The registered enrollment target is 2,373 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02003612 has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 2,373 participants
- Enrollment target
Study Summary
A retrospective analysis of historical data looking at hematological remission and survival in adult relapsed / refractory B-precursor acute lymphoblastic leukemia patients.
Primary Outcome
To estimate the proportion of patients in hematological complete remission (CR) for R/R Philadelphia chromosome negative (Ph-) B-precursor ALL patients following relapse or salvage treatment, excluding patients with a first remission duration of \>12 months in first salvage (ie, patients with late relapse in first salvage)
Interventions
- OTHER Not applicable - observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,373 participants |
| Start Date | 2013-10-01 |
| Est. Completion | 2014-04-28 |
What the finished NCT02003612 record still lists
NCT02003612 is an observational study that tracks outcomes without assigning an intervention. Its 2,373 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Not applicable - observational study is the first listed.
NCT02003612 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02003612 about?
NCT02003612 is a clinical study titled "Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia". A retrospective analysis of historical data looking at hematological remission and survival in adult relapsed / refractory B-precursor acute lymphoblastic leukemia patients.
What is the current status of trial NCT02003612?
This trial is currently completed. The enrollment target is 2,373 participants. The study started on 2013-10-01. Estimated completion is 2014-04-28.
What interventions are being tested in trial NCT02003612?
The interventions under investigation include: Not applicable - observational study (OTHER).
Who is sponsoring clinical trial NCT02003612?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05868421 · 2,376 participants · NA
Veteran Social Support for Enhancing Use of Smoking Cessation Treatment
- NCT06747494 · 2,396 participants · NA
General vs Spinal in Total Joint Arthroplasty (TJA)
- NCT00025935 · 2,350 participants
Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI